Skip to main content
DaehanPharmaceutical logo

DaehanPharmaceutical — Investor Relations & Filings

Ticker · 023910 ISIN · KR7023910003 KO Manufacturing
Open in API
Filings indexed 297 across all filing types
Latest filing 2024-03-20 Audit Report / Informat…
Country KR South Korea
Listing KO 023910

About DaehanPharmaceutical

https://www.dhnp.co.kr/

Daehan Nupharm is a pharmaceutical company engaged in the research, development, and manufacturing of a diverse portfolio of healthcare products. The company's business is structured around four core areas: human pharmaceuticals, offering a range of therapeutic treatments; animal health products for both companion and livestock animals; advanced bio-pharmaceuticals, with a focus on next-generation technologies like cell therapy; and health functional foods. Established initially in the animal health sector, the company leverages its dedicated Central and Bio Research Institutes to drive innovation and develop solutions for global markets. The R&D efforts concentrate on strengthening technological capabilities and advancing new treatment modalities.

Recent filings

Filing Released Lang Actions
감사보고서제출
Audit Report / Information Classification · 1% confidence The document is a regulatory filing from the Korea Exchange (KRX) system titled 'Audit Report Submission' (감사보고서 제출). It provides the audit opinion, key financial data, and confirmation of the auditor's report receipt for the fiscal year. While it contains financial data, it is a formal regulatory disclosure of the audit results rather than the full annual report (10-K) or a simple announcement of report publication (RPA). Given the specific nature of audit opinion disclosure in the Korean market, it falls under the Audit Report category. FY 2023
2024-03-20 Korean
사업보고서 (2023.12)
Audit Report / Information Classification · 1% confidence The document is a comprehensive 'Audit Report' (감사보고서) for the fiscal year 2023, including the independent auditor's opinion, financial statements (Balance Sheet, Income Statement, Statement of Changes in Equity, Cash Flow Statement), and detailed notes. It is not an Annual Report (10-K) as it lacks the management discussion and analysis (MD&A) and business overview typical of a full 10-K, and it is not a mere announcement (RPA) because it contains the full financial data and audit findings. FY 2023
2024-03-20 Korean
주식등의대량보유상황보고서(약식)
Major Shareholding Notification Classification · 1% confidence The document is a 'Report of Large Shareholding' (주식등의 대량보유상황보고서), which is a regulatory filing required when an entity acquires a significant percentage of a company's shares. In the context of Korean financial regulations (as indicated by the Korean text and references to the Financial Services Commission), this is a standard 'Major Shareholding Notification' (often referred to as a 5% report). It details the shareholding changes of Fidelity Management & Research Company LLC in Daehan Pharmaceutical Co., Ltd.
2024-03-20 Korean
주주총회소집공고
Proxy Solicitation & Information Statement Classification · 1% confidence The document is a 'Notice of General Meeting of Shareholders' (주주총회소집공고) for Daihan Pharmaceutical Co., Ltd. It contains the agenda for the 60th Annual General Meeting, including financial statement approval, director appointments, and dividend proposals. It also includes detailed financial statements (balance sheet, income statement, etc.) and management's discussion of business operations. This type of document is a formal proxy solicitation and information statement provided to shareholders to inform them of meeting details and request their votes, which fits the 'Proxy Solicitation & Information Statement' category.
2024-03-12 Korean
의결권대리행사권유참고서류
AGM Information Classification · 1% confidence The document is titled '의결권대리행사권유참고서류' (Reference Document for Solicitation of Proxy) and contains detailed information regarding the upcoming Annual General Meeting (AGM), including the date, purpose, and proxy solicitation details. While it includes financial statements, these are provided as part of the materials for the shareholders' meeting. According to the filing definitions, materials shared for the AGM are classified as AGM-R.
2024-03-12 Korean
주주총회소집결의
AGM Information Classification · 1% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) for Daehan Pharmaceutical. It outlines the date, location, and agenda items (such as financial statement approval, director appointments, and remuneration limits). This type of document is a standard proxy solicitation or notice of meeting sent to shareholders to inform them of upcoming voting matters, which falls under the Proxy Solicitation & Information Statement category.
2024-02-21 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.